Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL By Ogkologos - December 12, 2024 785 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR FDA Approves Cabozantinib for Adults and Paediatric Patients 12 Years of... April 18, 2025 FDA Approves Mirdametinib for Adult and Paediatric Patients with NF1 Who... March 20, 2025 Study of More than Half a Million Women Links Regular Mammograms... March 10, 2021 Low Risk of Cardiotoxicity with Immune Checkpoint Inhibitor Monotherapy or Combination... December 9, 2020 Load more HOT NEWS Artificial Intelligence for Diagnosis and Gleason Grading of Prostate Cancer Idecabtagene Vicleucel Prolongs PFS and Improves Response Compared with Standard Regimens... EMA Recommends Extension of Therapeutic Indications for Zanubrutinib EMA Recommends Granting a Marketing Authorisation for Fruquintinib
